The main limitation to the success of central nervous system (CNS) therapies lies in the
difficulty for drugs to cross the blood–brain barrier (BBB) and reach the brain. Regarding its …

The management of the central nervous system (CNS) disorders is challenging, due to the
need of drugs to cross the blood‒brain barrier (BBB) and reach the brain. Among the …

Nanostructured lipid carriers (NLC), comprises of a blend of solid and liquid lipids which
results in a partially crystallized lipid system and imparts many advantages over solid lipid …

The diagnosis and treatment of neurological ailments always remain an utmost challenge for
research fraternity due to the presence of BBB. The intranasal route appeared as an …

The blood-brain barrier and the blood-cerebrospinal fluid barrier are major obstacles in
central nervous system (CNS) drug delivery, since they block most molecules from entering …

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

Central nervous system (CNS) disorders (eg, multiple sclerosis, Alzheimer's disease, etc.)
represent a growing public health issue, primarily due to the increased life expectancy and …

The blood–brain barrier (BBB) restricts the transport of potential therapeutic moieties to the
brain. Direct targeting the brain via olfactory and trigeminal neural pathways by passing the …

The blood-brain barrier (BBB) is a dynamic interface between the peripheral blood supply
and the cerebral parenchyma, controlling the transport of material to and from the brain …

Lipid-based drug-delivery nanoparticles, including non-lamellar-type, mesophasic
nanostructured materials of lyotropic liquid crystals (LLCs), have been a topic of interest for …